Close

BD Receives FDA Approval for the BD FocalPoint™ GS Imaging System

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

WHO Supplies Medical Equipment for Post-Marburg...

In a recent move, the World Health Organization has...

Life Sciences Sector Plan Sets UK...

Main Article: UK Life Sciences Sector Plan Sets Sights...

UK Government Launches Ambitious Life Sciences...

Government Unveils Life Sciences Roadmap for Growth and Innovation London,...

Highly Customized Treatments to Offer Specialized...

The Human Medicines Regulations 2025, which came into force...
BD Diagnostics, a segment of BD announced that it received U.S. FDA Premarket Approval (PMA) for the BD FocalPoint™ GS Imaging System. This innovative new system is designed to enhance cervical cancer screening for cytology laboratories using the BD SurePath™ Pap test slides to detect evidence of squamous carcinoma, adenocarcinoma and their usual precursor conditions.

BD Diagnostics, a segment of BD announced that it received U.S. FDA Premarket Approval (PMA) for the BD FocalPoint™ GS Imaging System. This innovative new system is designed to enhance cervical cancer screening for cytology laboratories using the BD SurePath™ Pap test slides to detect evidence of squamous carcinoma, adenocarcinoma and their usual precursor conditions.

Vincent A. Forlenza, BD Executive Vice President, The launch of the BD FocalPoint™ GS System represents a key milestone in our effort to expand BD’s presence in cancer diagnostics . It is the first in a series of innovative products aimed at improving the detection and clinical management of cancer, resulting from our TriPath acquisition.

The key to detecting cervical cancer early is regular Pap testing. However, limitations exist with current technologies. Approximately one-third of Pap smear false negatives can be attributed to screening and interpretive errors in which abnormal cells are incorrectly classified.

Wayne Brinster, Vice President and General Manager, BD Diagnostics – TriPath said, Our clinical trial results give us confidence that the BD FocalPoint™ GS Imaging System will provide cytology labs with the advanced tool they need to improve cervical cancer detection and enhance their productivity. It demonstrates BD’s commitment to providing innovative, world-class products and services for the oncology market that help improve patient outcomes by offering clinicians better tools to detect and manage disease

Latest stories

Related stories

WHO Supplies Medical Equipment for Post-Marburg Virus Heal

In a recent move, the World Health Organization has...

Life Sciences Sector Plan Sets UK on Global Growth Track

Main Article: UK Life Sciences Sector Plan Sets Sights...

UK Government Launches Ambitious Life Sciences Sector Plan

Government Unveils Life Sciences Roadmap for Growth and Innovation London,...

Highly Customized Treatments to Offer Specialized Care to UK

The Human Medicines Regulations 2025, which came into force...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back